SUPPLEMENTAL TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b), 1.97(c), or 1.97(d) In Re Application of: U.S. Serial No. Filing Date 10/825,635 Filing Date April 15, 2004 Filing Date K. I. Wyrozebski Lee 1714

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR § 1.97(b) \bowtie The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114. 37 CFR § 1.97(c) П The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of: 1. a Final Action under § 1.113, 2. a Notice of Allowance under § 1.311, or

and is accompanied by either:

3.

the fee as set forth in § 1.17(p), or
the following statement under § 1.97(e)(1): each item of information contained
in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than
three months prior to the filing of the information disclosure statement.

an action that otherwise closes prosecution in the application,

37 CFR § 1.97(d)

The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby request consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith.					
Legible copies of references are enclosed where necessary.					
 ☑ This application is a: ☐ Continuation / Divisional, ☑ Continuation-in-Part, 					
of USSN 10/686,951, filed October 15, 2003 which claims priority from USSN 60/418,482, filed October 15, 2002 and USSN 60/460,714, filed April 4, 2003. This application is a also continuation-in-part of USSN 10/687,508, filed October 15, 2003 which claims priority from USSN 60/418,482, filed October 15, 2002 and USSN 60/460,714, filed April 4, 2003. Copies of the cited references are ☐ enclosed; ☒ not enclosed. References are available in the parent application(s) if not enclosed.					
The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account Number 05-1712. A duplicate copy of this form is enclosed.					
December 7, 2007/Stephen Timmins/					
Date Attorney for Applicants Registration No. 48,481					
ExxonMobil Chemical Co. Law Technology P.O. Box 2149					

ExxonMobil Chemical Co. Law Technology P.O. Box 2149 Baytown, Texas 77522-2149 Phone: 281-834-2866

Fax: 281-834-2495

_1 OF <u>1</u> FORM - 1449 SHEET

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY, DOCKET NO.	SERIAL NO.				
2003B043B	10/825,635				
Α	PPLICANT				

Abhari et al.

FILING DATE GROUP (Use several sheets if necessary)

(Use several sheets if necessary)				FILI	NG DATE		GROUP	
			April	April 15, 2004		1714		
			U.S. PATI	ENT DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT	
		4,886,853	12/12/1989	Foster, et al.	CLARGO	gen cures		
		4,929,509	05/29/1990	Godfrey				
		5,041,251	08/20/1991	McCoskey, et al.				
		5,185,398	02/09/1993	Kehr, et al.				
		5,367,022	11/22/1994	Kiang, et al.				
		5,397,843	11/22/1994	Kiang, et al.				
		5,723,546	03/03/1998	Sustic				
		5,747,621	05/05/1998	Resconi, et al.				
		5,869,555	02/09/1999	Simmons, et al.				
		5,942,569	08/24/1999	Simmons, et al.				
		5,994,437	11/30/1999	Lebez, et al.				
		6,214,952	04/10/2001	Sadatoshi, et al.				
		6,228,948	05/08/2001	Flaris, et al.				
		6,391,974	05/21/2002	Ogawa, et al.				
		6,559,211	05/06/2003	Zhao, et al.				
		6,613,816	09/02/2003	Mahdi, et al.				
		6,774,069	08/10/2004	Zhou, et al.				
		6,784,250	08/31/2004	Kijima				
		6,797,774	09/28/2004	Kijima				
		6,833,404	12/21/2004	Quinn, et al.				
		6,858,676	02/22/2005	Johoji, et al.				
		6,897,261	05/24/2005	Machida, et al.				
		6,984,680	01/10/2006	Quinn				
		7,064,163	06/20/2006	Shida				
		7,101,926	09/05/2006	McMichael, et al.				
		7,148,305	12/12/2006	Stevens, et al.				
		7,169,871	01/30/2007	Morini, et al.				
				ATENT DOCUMENTS				
		DOCUMENT NUMBER	PUBL DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		NOMBER	Date	COCITIE	CLAGO	GCBCLAGS	YES NO	
			 					
		I OTHER DISCLOSUR	I L ES (Including Auth	nor, Title, Date, Pertinent	Pages of Publi	cation, Etc.)	ı	
XAMINER		DATE CONSIDERED						

and not considered. Include copy of this form with next comment to applicant